Invention Grant
- Patent Title: Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells
-
Application No.: US15455575Application Date: 2017-03-10
-
Publication No.: US09849128B2Publication Date: 2017-12-26
- Inventor: Remi-Martin Laberge , Judith Campisi , Albert Davalos , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jennifer Elisseeff , Chaekyu Kim , Okhee Jeon
- Applicant: Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research , The John Hopkins University
- Applicant Address: US CA San Francisco US CA Novato US MN Rochester US MD Baltimore
- Assignee: Unity Biotechnology, Inc.,Buck Institute for Research on Aging,Mayo Foundation for Medical Education and Research,The John Hopkins University
- Current Assignee: Unity Biotechnology, Inc.,Buck Institute for Research on Aging,Mayo Foundation for Medical Education and Research,The John Hopkins University
- Current Assignee Address: US CA San Francisco US CA Novato US MN Rochester US MD Baltimore
- Agency: Wilson, Sonsini, Goodrich & Rosati
- Agent Michael Schiff
- Main IPC: A61K31/417
- IPC: A61K31/417 ; A61K31/496 ; A61K31/728 ; A61K31/4178
Abstract:
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Public/Granted literature
Information query
IPC分类:
